CDX-2 and HER-3 Expression in Canine Gastric and Colorectal Adenocarcinomas

Alan R Doster, J. Y. Yhee, J. H. Kim, K. S. Im, J. H. Sur

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CDX-2 is used as a specific cell marker for human intestinal adenocarcinoma. In human studies, HER-3 overexpression predicts poor survival for patients with various cancers including gastric cancer. Gastrointestinal adenocarcinoma is less common in dogs than in man and the expression of immunological markers by the canine tumours has not yet been extensively studied. CDX-2 and HER-3 expression was determined in 18 canine gastrointestinal adenocarcinomas: 13 were of colorectal origin and five were of gastric origin. CDX-2 expression was predominantly observed in the nuclei of normal colonic epithelium and in neoplastic epithelium and neoplastic gastric epithelial cells that which had metastasized to the gastric lymph node. CDX-2 was expressed in 11 of 13 (84.6%) colorectal adenocarcinomas and in all five (100%) gastric adenocarcinomas. HER-3 was consistently expressed in the cytoplasm of neoplastic epithelial cells. HER-3 expression was detected in 12 of 13 (92.3%) colorectal and in all five (100%) gastric adenocarcinomas. CDX-2 and HER-3 may be useful markers for canine gastrointestinal adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalJournal of Comparative Pathology
Volume145
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

adenocarcinoma
Canidae
Stomach
stomach
Adenocarcinoma
dogs
Stomach Neoplasms
epithelial cells
epithelium
Epithelium
Epithelial Cells
neoplasms
stomach neoplasms
Tumor Biomarkers
lymph nodes
Cytoplasm
cytoplasm
Lymph Nodes
Dogs
Survival

Keywords

  • CDX-2
  • Dog
  • Gastrointestinal adenocarcinoma
  • HER-3
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • veterinary(all)

Cite this

CDX-2 and HER-3 Expression in Canine Gastric and Colorectal Adenocarcinomas. / Doster, Alan R; Yhee, J. Y.; Kim, J. H.; Im, K. S.; Sur, J. H.

In: Journal of Comparative Pathology, Vol. 145, No. 1, 01.07.2011, p. 12-19.

Research output: Contribution to journalArticle

Doster, Alan R ; Yhee, J. Y. ; Kim, J. H. ; Im, K. S. ; Sur, J. H. / CDX-2 and HER-3 Expression in Canine Gastric and Colorectal Adenocarcinomas. In: Journal of Comparative Pathology. 2011 ; Vol. 145, No. 1. pp. 12-19.
@article{f6a7ea4542ce429fbed4a65a38a0f842,
title = "CDX-2 and HER-3 Expression in Canine Gastric and Colorectal Adenocarcinomas",
abstract = "CDX-2 is used as a specific cell marker for human intestinal adenocarcinoma. In human studies, HER-3 overexpression predicts poor survival for patients with various cancers including gastric cancer. Gastrointestinal adenocarcinoma is less common in dogs than in man and the expression of immunological markers by the canine tumours has not yet been extensively studied. CDX-2 and HER-3 expression was determined in 18 canine gastrointestinal adenocarcinomas: 13 were of colorectal origin and five were of gastric origin. CDX-2 expression was predominantly observed in the nuclei of normal colonic epithelium and in neoplastic epithelium and neoplastic gastric epithelial cells that which had metastasized to the gastric lymph node. CDX-2 was expressed in 11 of 13 (84.6{\%}) colorectal adenocarcinomas and in all five (100{\%}) gastric adenocarcinomas. HER-3 was consistently expressed in the cytoplasm of neoplastic epithelial cells. HER-3 expression was detected in 12 of 13 (92.3{\%}) colorectal and in all five (100{\%}) gastric adenocarcinomas. CDX-2 and HER-3 may be useful markers for canine gastrointestinal adenocarcinoma.",
keywords = "CDX-2, Dog, Gastrointestinal adenocarcinoma, HER-3, Immunohistochemistry",
author = "Doster, {Alan R} and Yhee, {J. Y.} and Kim, {J. H.} and Im, {K. S.} and Sur, {J. H.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.jcpa.2010.11.007",
language = "English (US)",
volume = "145",
pages = "12--19",
journal = "Journal of Comparative Pathology",
issn = "0021-9975",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - CDX-2 and HER-3 Expression in Canine Gastric and Colorectal Adenocarcinomas

AU - Doster, Alan R

AU - Yhee, J. Y.

AU - Kim, J. H.

AU - Im, K. S.

AU - Sur, J. H.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - CDX-2 is used as a specific cell marker for human intestinal adenocarcinoma. In human studies, HER-3 overexpression predicts poor survival for patients with various cancers including gastric cancer. Gastrointestinal adenocarcinoma is less common in dogs than in man and the expression of immunological markers by the canine tumours has not yet been extensively studied. CDX-2 and HER-3 expression was determined in 18 canine gastrointestinal adenocarcinomas: 13 were of colorectal origin and five were of gastric origin. CDX-2 expression was predominantly observed in the nuclei of normal colonic epithelium and in neoplastic epithelium and neoplastic gastric epithelial cells that which had metastasized to the gastric lymph node. CDX-2 was expressed in 11 of 13 (84.6%) colorectal adenocarcinomas and in all five (100%) gastric adenocarcinomas. HER-3 was consistently expressed in the cytoplasm of neoplastic epithelial cells. HER-3 expression was detected in 12 of 13 (92.3%) colorectal and in all five (100%) gastric adenocarcinomas. CDX-2 and HER-3 may be useful markers for canine gastrointestinal adenocarcinoma.

AB - CDX-2 is used as a specific cell marker for human intestinal adenocarcinoma. In human studies, HER-3 overexpression predicts poor survival for patients with various cancers including gastric cancer. Gastrointestinal adenocarcinoma is less common in dogs than in man and the expression of immunological markers by the canine tumours has not yet been extensively studied. CDX-2 and HER-3 expression was determined in 18 canine gastrointestinal adenocarcinomas: 13 were of colorectal origin and five were of gastric origin. CDX-2 expression was predominantly observed in the nuclei of normal colonic epithelium and in neoplastic epithelium and neoplastic gastric epithelial cells that which had metastasized to the gastric lymph node. CDX-2 was expressed in 11 of 13 (84.6%) colorectal adenocarcinomas and in all five (100%) gastric adenocarcinomas. HER-3 was consistently expressed in the cytoplasm of neoplastic epithelial cells. HER-3 expression was detected in 12 of 13 (92.3%) colorectal and in all five (100%) gastric adenocarcinomas. CDX-2 and HER-3 may be useful markers for canine gastrointestinal adenocarcinoma.

KW - CDX-2

KW - Dog

KW - Gastrointestinal adenocarcinoma

KW - HER-3

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=79956033070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956033070&partnerID=8YFLogxK

U2 - 10.1016/j.jcpa.2010.11.007

DO - 10.1016/j.jcpa.2010.11.007

M3 - Article

C2 - 21238975

AN - SCOPUS:79956033070

VL - 145

SP - 12

EP - 19

JO - Journal of Comparative Pathology

JF - Journal of Comparative Pathology

SN - 0021-9975

IS - 1

ER -